Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Jan;44(1):385-387.
doi: 10.1007/s10072-022-06405-0. Epub 2022 Sep 14.

Rapid versus slow withdrawal of antiepileptic monotherapy in two-year seizure-free adults patients with epilepsy (RASLOW) study: a pragmatic multicenter, prospective, randomized, controlled study Reply to letter to the editor

Affiliations
Comment

Rapid versus slow withdrawal of antiepileptic monotherapy in two-year seizure-free adults patients with epilepsy (RASLOW) study: a pragmatic multicenter, prospective, randomized, controlled study Reply to letter to the editor

Edoardo Ferlazzo et al. Neurol Sci. 2023 Jan.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Ferlazzo E, Giussani G, Gasparini S et al (2022) Rapid versus slow withdrawal of antiepileptic monotherapy in two-year seizure-free adults patients with epilepsy (RASLOW) study: a pragmatic multicentre, prospective, randomized, controlled study. Neurol Sci 43(8):5133–5141. https://doi.org/10.1007/s10072-022-06121-9
    1. Panigrahi B, Tripathi M (2022) Rapid versus slow withdrawal of antiepileptic monotherapy in 2‑year seizure‑free adult patients with epilepsy (RASLOW) study: a pragmatic multicenter, prospective, randomized, and controlled study-letter to the editor. Neurol Sci. https://doi.org/10.1007/s10072-022-06368-2
    1. Gasparini S, Ferlazzo E, Giussani G, Italiano D, Cianci V, Sueri C, Spina E, Beghi E, Aguglia U (2016) Rapid versus slow withdrawal of antiepileptic monotherapy in 2-year seizure-free adult patients with epilepsy (RASLOW) study: a pragmatic multicentre, prospective, randomized, controlled study. Neurol Sci 37(4):579–583. https://doi.org/10.1007/s10072-016-2483-3 - DOI

Substances